| abstract |
The present invention relates to a method of administering GX-H9, a human growth hormone fusion protein, for treating growth hormone deficiency. Specifically, the present invention provides a pharmaceutical composition comprising a hGH fusion protein, GX-H9, and a pharmaceutically acceptable carrier, wherein said fusion protein (GX-H9) is administered once a week at a dose of 0.1 to 0.3 mg / Or is administered once every two weeks at a dose of 0.1 to 0.4 mg per kg body weight of a patient, to a pharmaceutical composition for treating a growth hormone deficiency. In addition, the present invention relates to a method of administering gX-H9, a hGH fusion protein, to a patient suffering from growth hormone deficiency, once a week at a dosage of 0.1 to 0.3 mg per kg body weight of a patient, or 0.1 to 0.4 mg per kg of a patient's body weight Wherein the method comprises the step of administering the composition to a human in need thereof. |